Metformin

Metformin is primarily used for the treatment of type 2 diabetes mellitus, where it serves as a first-line therapeutic agent for glycemic control. The available evidence shows ongoing clinical investigation into both its established uses and potential expanded applications.

Type 2 Diabetes Management

Current clinical trials demonstrate continued evaluation of metformin's role in diabetes care. A Phase 3 study (NCT06141980) is examining the long-term safety and efficacy of DWP16001, likely a metformin-containing formulation, in type 2 diabetes patients. Additionally, a registry-based randomized controlled trial (NCT06627322) is investigating metformin's use in type 2 diabetes patients with cardiovascular risk factors, suggesting ongoing research into its cardioprotective benefits.

One terminated Phase 3 trial (NCT00449605) had compared glimepiride versus rimonabant when added to metformin therapy, indicating metformin's role as background therapy in combination treatment approaches.

Pregnancy-Related Applications

Metformin's use during pregnancy is under active clinical investigation. The POEM Study (NCT02947503), a Phase 3 trial currently recruiting participants, is specifically evaluating pregnancy outcomes associated with metformin use. Another suspended study (NCT05932251) was exploring precision medicine approaches for diabetes management during pregnancy, which likely included metformin given its established safety profile in pregnancy.

Evidence Limitations

The current evidence base from recent publications does not provide detailed clinical trial results for metformin's specific therapeutic applications. While the compound has well-established uses in clinical practice, the available recent literature focuses primarily on other therapeutic areas and does not contain comprehensive efficacy or safety data for metformin's clinical applications.

This information is for educational purposes only and should not replace professional medical advice. Patients should consult their healthcare providers for personalized treatment recommendations.